News

MediciNova Launches Phase 2b/3 Trial of Ibudilast for ALS

MediciNova has launched the Phase 2b/3 clinical trial that will explore the potential of ibudilast (MN-166) in patients with amyotrophic lateral sclerosis (ALS). Pending the success of the trial, the collected data will support the submission of a new drug application and the approval of ibudilast…

Cytokinetics Renews Partnership With ALS Association

Citing research progress and other efforts, the late-stage biopharmaceutical company Cytokinetics has reaffirmed its burgeoning partnership with the ALS Association in its fight against amyotrophic lateral sclerosis (ALS). For starters, the company is renewing its sponsorship of the association’s national Walk to Defeat ALS fundraisers, as well…

Histamine-Related Genes May Become Biomarkers and Therapeutic Targets for ALS, Mouse Study Suggests

Histamine-related genes are promising disease biomarkers and therapeutic targets to slow amyotrophic lateral sclerosis (ALS) progression, a mouse study suggests. The study, “Histaminergic transmission slows progression of amyotrophic lateral sclerosis,” was published in the Journal of Cachexia, Sarcopenia and Muscle. ALS is a progressive neurodegenerative disorder…